title: Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab.
abstract: Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.
authors.affiliation: Department of Internal Medicine, The Catholic University of Korea, College of Medicine, 520-2 Daeheung-dong, Jung-gu, Daejeon, Korea.
authors.forename: Su-Jin
authors.initials: SJ
authors.lastname: Moon
authors.forename: Hee-Jeoung
authors.initials: HJ
authors.lastname: Yoon
authors.forename: Sung-Ho
authors.initials: SH
authors.lastname: Her
authors.forename: Jong-Min
authors.initials: JM
authors.lastname: Lee
authors.forename: Ho-Jung
authors.initials: HJ
authors.lastname: An
authors.forename: Yune-Jeong
authors.initials: YJ
authors.lastname: Lee
authors.forename: Seung-Won
authors.initials: SW
authors.lastname: Jin
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects*; D002305:Cardiac Tamponade / Q000209:etiology* / Q000628:therapy; D004632:Emergency Medical Services; D006470:Hemorrhage / Q000209:etiology* / Q000628:therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D007723:Korea; D008297:Male; D020519:Pericardiocentesis; D010493:Pericarditis / Q000209:etiology* / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab
references.citation: Cardiology. 2007;107(3):172-7
references.pmid: 16940721
references.citation: Am J Ther. 2004 Jul-Aug;11(4):302-7
references.pmid: 15266223
references.citation: J Interv Cardiol. 2004 Apr;17(2):65-70
references.pmid: 15104767
references.citation: Circulation. 2004 May 11;109(18):2203-6
references.pmid: 15117843
references.citation: J Interv Cardiol. 2003 Oct;16(5):381-4
references.pmid: 14603795